Pages Menu
Categories Menu

Blog

Pre-exposure prophylaxis dramatically protects against HIV infection: UK Proud study results published

Posted by on Oct 26, 2015 in Uncategorized | 0 comments

  Results of the United Kingdom PROUD study were published in the September 9th issue of the Lancet, following their earlier presentation at the Conference on Retroviruses and Opportunistic Infections 2015, in Seattle [1]. As reported at CROI, pre-exposure prophylaxis (PrEP) dramatically reduces the risk of HIV infection in gay men and transgender females by 86%. In addition, there was no evidence of increased high risk sex in those receiving PrEP and there was also no increase in drug resistant HIV among those receiving PrEP.  ...

read more

Panobinostat phase 1 trial provides limited advance in HDAC inhibitor pipeline

Posted by on Oct 26, 2015 in Uncategorized | 0 comments

The first clinical trial of Panobinostat by the Department of Infectious Diseases and Department of Immunology at Aarhus University Hospital, Denmark marks the next step in the development of the histone deactylase (HDAC) inhibitor group of latency reversal agents [1]. Thomas Rasmussen and colleagues describe results from this single-arm phase1/2 clinical trial of the second HDAC in clinical development. This paper was published in October 2014 in a new journal, Lancet HIV, with limited accessibility. It has recently become available on the...

read more

Theo Smart’s Partial Publications/Portfolio list (a work in progress)

Posted by on Jan 21, 2015 in Our bios and CVs | 0 comments

Major projects with published output accessible online, in order of the most recent (see end for freelance news coverage) Parent Project Muscular Dystrophy Medical writer: Submission of a Proposed Draft Guidance for Industry on Developing Drugs for Treatment of Duchenne Muscular Dystrophy; Establishment of a Public Docket (see here) Cover letter for submission: The Draft Guidance for Industry on Developing Drugs for the Treatment of Duchenne Muscular Dystrophy (see here) Accolades and media coverage of the Draft Guidance: Wall Street Journal:...

read more

Theo Smart’s CV

Posted by on Jan 10, 2015 in Our bios and CVs | 2 comments

This is the short one page version: Theo Smart-CV-AmericanEnglish And this is the longer version: Theo Smart-CV-AmericanEnglish-long2

read more

The use of convalescent plasma or serum

Posted by on Dec 13, 2014 in Blog posts, Conference coverage, News | 0 comments

The use of convalescent plasma or serum

Over the summer, an international network of blood regulators developed a physician’s paper for regulators, and for anyone who might wish to become involved, outlining the reasons to consider antibodies derived from blood or convalescent plasma, or ultimately, hyperimmune globulins as a potential therapy in a filovirus outbreak. They provided an assessment of the previous experience both in animals and in humans using antibodies in other diseases, and importantly emphasize the role of regulatory agencies and the considerations that should be...

read more

Ebola vaccines in development

Posted by on Dec 13, 2014 in Blog posts, Conference coverage, News | 0 comments

Ebola vaccines in development

  The following table includes the leading candidates, however a number of these are not yet ready for a phase-1 trial but may be coming into trial over the next three to six months, and some are slightly longer term. Vaccine Manufacturers (developers): Vaccine details: Testing timeline: ChAd3-ZEBOV GlaxoSmithKline (National Institutes of Health (NIH) Chimpanzee adenovirus type-3 vector In phase-1 trials; phase-3 trials are planned for December 2014 or January 2015 rVSV-Ebov Newlink Genetics (the Public Health Agency of Canada) [Note,...

read more

Experimental therapies being evaluated to treat Ebola

Posted by on Dec 13, 2014 in Blog posts, Conference coverage, News | 1 comment

Experimental therapies being evaluated to treat Ebola

Experimental therapies for Ebola include new compounds, as well as existing drugs approved for other purposes which demonstrate activity in laboratory models and which potentially could be repurposed. At least something is known about the approved drug’s safety profile, though the doses used for Ebola may not be the same. Each of the following potential therapeutics have been prioritized for consideration based on the availability of non-human primate efficacy data following a challenge from a filovirus (the family of viruses to which Ebola...

read more

WHO’s Comprehensive Plan to Rapidly Develop Therapeutics and Vaccines

Posted by on Dec 13, 2014 in Blog posts, Conference coverage, News | 0 comments

WHO’s Comprehensive Plan to Rapidly Develop Therapeutics and Vaccines

Despite research into Ebola vaccines and therapeutics over the past decade, no product has been fully evaluated and approved for human use. This means that the only way to deal with this unprecedented outbreak has been to use the same basic public health and supportive care measures that were available in the past. Having an effective vaccine could have stopped the spread of the epidemic in it’s tracks and help prevent future outbreaks, while the development and availability of safe and effective therapeutics could have improved survival and...

read more

Lessons learned in the ‘Hot Zone’

Posted by on Dec 13, 2014 in Blog posts, Conference coverage, News | 0 comments

Lessons learned in the ‘Hot Zone’

“The most difficult part for a clinician is when you don’t know if the patient has Ebola or not,” said Dr. Frederique Jacquerioz at the recent American Society of Tropical Medicine and Hygiene Meeting in New Orleans. Despite the title of her presentation ‘from the ‘Hot Zone’: A Clinician’s Perspective on Confronting Ebola Virus in West Africa’, she said that only about 10% of Ebola patients in West Africa present with any sign of bleeding. Dr. Jacquerioz has been the Director of the Tulane Clinical Training Program in Sierra Leone and...

read more

How did this Ebola outbreak emerge and what have we learned?

Posted by on Dec 2, 2014 in Blog posts, Conference coverage, News | 0 comments

How did this Ebola outbreak emerge and what have we learned?

At the launch of the 2014 American Society of Tropical Medicine and Hygiene Conference in New Orleans, Bill Gates said the meeting was talking place at a critical moment in the history of global health — in the midst of an Ebola epidemic in a part of the world that had already been hit hard by other diseases as well as poverty and civil strife. “I think it’s worth noting that this particular Ebola outbreak was a unique event in many ways. The disease had formerly presented itself in Central Africa; now it was in West Africa. It had limited...

read more